Tuesday, 23 October 2018
Latest news
Main » Seattle Genetics, Inc. (SGEN) Stake Lowered by National Planning Corp

Seattle Genetics, Inc. (SGEN) Stake Lowered by National Planning Corp

13 January 2018

JGP Global Gestao de Recursos Ltda. now owns 20,603 shares of the biotechnology company's stock worth $1,121,000 after acquiring an additional 969 shares during the last quarter. The Whalerock Point Partners Llc holds 36,190 shares with $1.97 million value, down from 48,790 last quarter. Ao Smith Corp now has $11.19 billion valuation. The lowest price the stock reached in the last trading day was $31.88 and compares with the $12.29 52-week low. About 15,598 shares traded.

Analyst research firms are expressing bullish stance on Seattle Genetics, Inc. After $-0.19 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 142.11 % negative EPS growth. The total amount of shares outstanding is 145.29 million, giving the company a market capitalization of about 7.76 billion. Ecor1 Capital Llc who had been investing in Regulus Therapeutics Inc for a number of months, seems to be bullish on the $127.87 million market cap company. The stock decreased 3.00% or $1.6 during the last trading session, reaching $51.78. According to the latest data, the consensus recommendation for Seattle Genetics, Inc. They set an outperform rating and a $58.00 price target on the stock. Carl Domino stated it has 0.35% of its portfolio in Seattle Genetics, Inc. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Therefore 100% are positive. TheStreet upgraded Seattle Genetics from a "d" rating to a "c" rating in a report on Thursday, November 16th. The firm earned "Buy" rating on Wednesday, December 7 by Chardan Capital Markets. Cowen & Co has "Hold" rating and $5400 target. The company was maintained on Thursday, September 14 by RBC Capital Markets. The firm has "Hold" rating by Needham given on Monday, January 30. The firm earned "Buy" rating on Wednesday, January 4 by Maxim Group. The firm has "Hold" rating by Oppenheimer given on Wednesday, August 16. The stock of A. O. Smith Corporation (NYSE:AOS) earned "Buy" rating by Jefferies on Friday, September 23. $1.22 million worth of Seattle Genetics, Inc. (NASDAQ:BLMN) for 292,935 shares.

Investors sentiment increased to 1.14 in Q3 2017.

Since January 1, 0001, it had 0 insider purchases, and 17 sales for $9.99 million activity. It dropped, as 15 investors sold K12 Inc. shares while 35 reduced holdings. 11 funds opened positions while 16 raised stakes. Shine Inv Advisory Services, a Colorado-based fund reported 157 shares. Gsa Capital Prtn Ltd Liability Partnership stated it has 203,815 shares or 0.02% of all its holdings. 4,775 are held by Griffin Asset Management. Moreover, Technologies Crossover Mngmt Vii Limited has 2.73% invested in K12 Inc. (NASDAQ:RGLS). Morgan Stanley owns 5,699 shares for 0% of their portfolio. Northern Tru accumulated 1.35 million shares. Bnp Paribas Arbitrage has 22,221 shares for 0% of their portfolio. Patten Gru has invested 0% in A. O. Smith Corporation (NYSE:AOS). Comerica State Bank reported 0% stake. Cutera had 8 analyst reports since January 4, 2017 according to SRatingsIntel. MYGN's profit will be $16.62 million for 37.47 P/E if the $0.24 EPS becomes a reality.

Investors sentiment decreased to 0.78 in Q3 2017. 29 funds opened positions while 69 raised stakes. (SGEN) most recent 13F filing, the company has 24 new institutional holders - accounting for 3.58 million shares of its common stock. (NASDAQ:SGEN). Dupont Cap invested in 0.01% or 7,861 shares. Fairfield Bush And owns 16,772 shares or 0.29% of their United States portfolio. Point72 Asia (Hong Kong) stated it has 732 shares. Hall Laurie J Trustee accumulated 340 shares. Qs Investors Limited Liability Company has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) traded down 1.36% on Tuesday, hitting $60.70. Seattle Genetics has a 12 month low of $45.31 and a 12 month high of $71.32. (NASDAQ:SGEN). Howe Rusling invested in 0% or 40 shares. The stock has a market cap of $7,450.00, a price-to-earnings ratio of -59.52 and a beta of 2.37. Ascend Cap Limited Liability Company invested in 164,648 shares or 0.34% of the stock. Capital Interest Ca reported 61,330 shares. Eventide Asset Mngmt Limited Liability Corp holds 1.62% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on February, 8.

JPMorgan Chase & Co. reissued their hold rating on shares of Seattle Genetics (NASDAQ:SGEN) in a research note issued to investors on Tuesday morning. Therefore 19% are positive. Manning & Napier Advisors LLC bought a new position in Seattle Genetics in the third quarter valued at approximately $140,098,000. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. (NASDAQ:SGEN) has "Hold" rating given on Monday, June 26 by Oppenheimer. The stock has "Buy" rating by H.C. Wainwright on Friday, October 27. The company was initiated on Thursday, October 6 by Mizuho. As per Friday, June 2, the company rating was maintained by Oppenheimer. The stock has "Hold" rating by Cantor Fitzgerald on Monday, June 26.

Since August 7, 2017, it had 0 insider buys, and 17 insider sales for $9.99 million activity. The insider Laber Larry sold 500 shares worth $20,250. Also, COO Eric Dobmeier sold 9,600 shares of Seattle Genetics stock in a transaction that occurred on Wednesday, November 15th. DRACHMAN JONATHAN G sold 8,502 shares worth $407,199.